-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang Sihua Pharmaceutical Group’s Guangxiang Pharmaceutical has received approval for the active pharmaceutical ingredient lacosamide.
Category:
Time：2022-05-17
Shijiazhuang Fourth Pharmaceutical Group has once again received good news from its research and development efforts. Recently, the active pharmaceutical ingredient—lacosamide—developed and submitted by the Group’s Hebei Guangxiang Pharmaceutical Co., Ltd. has been approved by the National Medical Products Administration and can now be officially used in marketed formulations.
Shijiazhuang Fourth Pharmaceutical Group has once again received good news in its research and development efforts. Recently, the active pharmaceutical ingredient—lacosamide—developed and submitted by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Fourth Pharmaceutical Group, has been approved by the National Medical Products Administration and can now be officially used in marketed formulations.
It is reported that lacosamide formulations are clinically primarily used for monotherapy and combination therapy of partial-onset seizures in epilepsy patients aged 4 years and older.
Previously, Shijiazhuang No. 4 Pharmaceutical’s lacosamide tablets in two specifications—50 mg and 100 mg—obtained drug registration certificates issued by the National Medical Products Administration and were deemed to have passed the evaluation of bioequivalence and therapeutic equivalence for generic drugs. The recent approval of the lacosamide active pharmaceutical ingredient will further enhance the product’s market competitiveness.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license